– USA, CA – MusclePharm Corporation (OTC: MSLP), a global provider of leading sports nutrition & lifestyle branded nutritional supplements, today announced the appointment of Paul Karr to its Board as a new independent Director.
With a history in financial reporting, issue resolution, and internal controls across numerous fields including pharmaceuticals, manufacturing, insurance and financial services at companies such as American Express and General Electric, Mr. Karr assumes the role of Audit Committee Chair.
“With his illustrious career at American Express, General Electric, Bristol-Myers Squibb, and Deloitte & Touche among other reputable companies, I’m very excited to welcome Paul Karr to the Board of Directors at MusclePharm. I’m confident that his appointment signals the strength of the brand and its ability to attract top-level talent,” said Board Chairman, Ryan Drexler.
“I am delighted to join the Board of MusclePharm at this important time in its development,” said Paul Karr. “I look forward to working with my fellow Board members and management to ensure that the company has the controls and governance to support its future growth.”
About MusclePharm Corporation
MusclePharm is an award-winning, worldwide leading sports nutrition & lifestyle company offering branded nutritional supplements. Its portfolio of recognized properties include the MusclePharm Sport Series, Essentials Series, and recently-launched Natural Series, as well as FitMiss – a product line designed specifically for female athletes. MusclePharm products are available in more than 100 countries globally, with its Combat Protein product lineup being the company’s most popular.
For more information : https://musclepharm.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
